Objective To investigate the molecular mechanism of Sansheng Hehuan Yin in treating lipid metabolism-related depression based on network pharmacology. Methods Target genes of Sansheng Hehuan Yin and those related to lipid metabolism-related depression were screened from databases. A “Chinese herbal compound-active ingredient-key target” network and a protein-protein interaction network were constructed, followed by GO and KEGG enrichment analyses. Results A total of 911 target genes of Sansheng Hehuan Yin and 9,017 disease-related target genes were identified, yielding 724 overlapping targets. Twenty-one core genes, including PTGS2, HSP90AA1, and ESR1, were screened from the PPI network. A total of 11,307 GO entries were enriched, involving biological processes such as protein phosphorylation and cellular response to lipid, cellular components such as membrane raft and dendrite, and molecular functions such as protein kinase activity. KEGG enrichment analysis identified 313 signaling pathways, including pathways in cancer, lipid and atherosclerosis, among others. Conclusion Sansheng Hehuan Yin may exert its therapeutic effects on lipid metabolism-related depression through multiple targets, components, and signaling pathways.

Objective This study was conducted to systematically analyze the epidemic status, core co-morbidities patterns and influencing factors of chronic diseases among elderly people aged 65 and above in FQ town in East China, so as to reveal the health burden characteristics and co-morbidities trends of the elderly population in this area, and provide empirical evidence for formulating precise prevention and control strategies and management programs for chronic diseases in accordance with the characteristics of grass-roots villages and towns. Methods A cross-sectional study design was adopted to collect health examination data of 12,028 elderly people aged 65 and above in FQ town in 2024. Prevalence and comorbidity of 8 common chronic diseases such as hypertension, diabetes mellitus and stroke were analyzed. Disease counting method was used to describe comorbidity combinations, and Apriori association rule algorithm was used to mine strong association patterns among diseases. Based on the health ecology model framework, single factor and multiple factor Logistic regression analysis were used to explore the influencing factors of chronic disease comorbidity from multiple aspects such as congenital traits, individual behavior, interpersonal network and living conditions. Results In FQ town, 64.9% of the elderly were included in chronic disease management, and the overall prevalence of chronic diseases was 20.2%. Hypertension had the highest prevalence Association rule analysis showed that the binary comorbidity pattern presented a highly concentrated feature,"diabetes→ hypertension"(Confidence 95.89%), Stroke→Hypertension (93.93% confidence) and "coronary heart disease→hypertension" There was age and gender heterogeneity in the co-morbid pattern: the co-morbid driving core shifted from metabolic diseases to "myocardial infarction→hypertension" and "chronic bronchitis→hypertension" in the age group of 75-79; the association of "chronic bronchitis→hypertension" appeared in the elderly women. Multivariate analysis showed that old age and overweight/obesity were independent risk factors for comorbidity, and obesity was the highest risk factor (OR=21.7). Conclusion Although the burden of chronic diseases in FQ town was lower than that reported in China, the metabolic and cardiovascular diseases co-morbidities pattern with hypertension as the core was very prominent and the correlation intensity was amazing. The study suggests that prevention and control of chronic diseases at the grass-roots level should break through the single-disease diagnosis and treatment thinking, implement synchronous blood pressure management for patients with diabetes and stroke, and formulate stratified and accurate health management and education strategies according to age and gender differences.

Objective From the perspective of China's health system, to evaluate the cost-effectiveness of cetuximab β combined with FOLFIRI (irinotecan + calcium folinate + fluorouracil) compared to single-agent FOLFIRI as first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer, providing economic evidence for clinical decision-making and medical insurance policy formulation. Method Based on a phase III clinical trial of cetuximab β combined with FOLFIRI, a three-state Markov model was constructed. The simulation cycle is 2 weeks (matching the FOLFIRI dosing regimen), and the simulation time range is 10 years (ensuring that 99% of cohort patients reach the death state). Output indicators include total cost and Quality-Adjusted Life Years (QALYs), to calculate the Incremental Cost Effectiveness Ratio (ICER); model robustness is verified through univariate sensitivity analysis, probabilistic sensitivity analysis, and scenario analysis. Cost data is calculated based on the per capita GDP in 2024 at 95,700 yuan/person, with both cost and utility discount rates set at 5%. Results The basic analysis showed that the total cost of the cetuximab β + FOLFIRI group was 162,791 yuan, with a cumulative gain of 1.08 QALYs; the total cost of the FOLFIRI group alone was 47,846 yuan, with a cumulative gain of 0.91 QALYs. Compared to the FOLFIRI group alone, the incremental cost of the combination therapy group was 114,945 yuan, and the incremental QALYs were 0.17, with an ICER of 676,147 yuan/QALY, which is higher than three times the per capita GDP of China in 2024. Sensitivity analysis showed that scenario analysis and sensitivity analysis demonstrated the robustness of the model. In 99.9% of simulations, the incremental cost for each QALY gained by the cetuximab β combined with FOLFIRI group was above 287,100 yuan. Conclusion At a threshold of three times the per capita GDP in China, cetuximab β combined with FOLFIRI as first-line treatment for RAS/BRAF wild-type mCRC patients in China is not cost-effective compared to FOLFIRI alone.

 Objective This paper aims to systematically review the clinical application value and development pathways of Guizhou Miao medicine in the field of rehabilitation. Methods Through literature review and problem analysis, the current practice status of Miao medicine in rehabilitation fields such as orthopedics, neurology, and chronic diseases was summarized, and the development bottlenecks were analyzed from aspects including theory, standards, research, talent, and industry. Results Miao medicine shows significant potential in pain management, functional recovery, and chronic disease adjustment, but it faces challenges such as insufficient modernization of theory, lack of standards, weak evidence-based support, and shortage of talents. Conclusion Measures such as theoretical innovation, standardization and evidence-based research, industrial integration, and talent cultivation should be taken to promote the scientific integration of Miao medicine into rehabilitation medicine, and to support the inheritance of ethnic medicine and the development of the health and wellness industry.

Objective To systematically analyze the key issues such as drug resistance, safety and irrational drug use faced by quinolone antibacterial drugs in clinical application in the past five years, and to explore the corresponding solutions. Methods systematically retrieved and sorted out domestic and international research, guidelines, monitoring reports and real-world data on quinolone antibacterial drugs from 2018 to 2023, with a focus on including evidence in areas such as plasmid-mediated resistance, serious adverse reactions, medication in special populations and antibacterial drug management. Results The detection rate of plasmid-mediated quinolone resistance (PMQR) genes has shown a rapid upward trend in China, and the quinolone resistance rate of multi-drug resistant bacteria generally exceeds 85%. Fluoroquinolone drugs carry serious black box warning risks such as aortic dissection and tendon rupture, and the problems of unindicated clinical use and non-standard dosage and treatment courses are prominent. New quinolones (such as nerofloxacin) remain effective against some drug-resistant bacteria. Conclusion The resistance situation of quinolone antibacterial drugs is severe, the safety risks need to be highly vigilant, and irrational drug use is widespread. In the future, it is necessary to strengthen the management of antibacterial drugs, promote individualized medication based on PK/PD, and accelerate the research and development of new drugs.Key words: Quinolone antibacterial drugs Plasmid-mediated drug resistance Drug safety; Medication for children Management of antibacterial drugs Therapeutic drug monitoring